Nicholas Wilcken

8.5k total citations
65 papers, 2.4k citations indexed

About

Nicholas Wilcken is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nicholas Wilcken has authored 65 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 28 papers in Cancer Research and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nicholas Wilcken's work include Breast Cancer Treatment Studies (26 papers), Cancer Treatment and Pharmacology (23 papers) and Estrogen and related hormone effects (15 papers). Nicholas Wilcken is often cited by papers focused on Breast Cancer Treatment Studies (26 papers), Cancer Treatment and Pharmacology (23 papers) and Estrogen and related hormone effects (15 papers). Nicholas Wilcken collaborates with scholars based in Australia, United Kingdom and United States. Nicholas Wilcken's co-authors include Davina Ghersi, Martin H.N. Tattersall, Anna K. Nowak, Martin R. Stockler, Thomas Ferguson, Annabel Goodwin, Rachel Dear, Charlene Thornton, Sharon K. Parker and Sue Carrick and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Nicholas Wilcken

64 papers receiving 2.3k citations

Peers

Countries citing papers authored by Nicholas Wilcken

Since Specialization

Citations

This map shows the geographic impact of Nicholas Wilcken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Wilcken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Wilcken more than expected).

Fields of papers citing papers by Nicholas Wilcken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Wilcken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Wilcken. The network helps show where Nicholas Wilcken may publish in the future.

Co-authorship network of co-authors of Nicholas Wilcken

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas Wilcken. A scholar is included among the top collaborators of Nicholas Wilcken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas Wilcken. Nicholas Wilcken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study 2022 ·Supportive Care in Cancer ·(unknown), (unknown), Linda Mileshkin, Richard W. Tothill, David D.L. Bowtell, Stephen Quinn, Anna DeFazio, Christos S. Karapetis, Nicholas Wilcken, Madhu Singh, Christopher Steer, Bo Gao, Mark Warren, Ian Collins, Narayan Karanth, (unknown), Penelope Schofield	4
2	91MO Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial 2022 ·Annals of Oncology ·N. Murray, Prudence A. Francis, Nicholas Zdenkowski, Nicholas Wilcken, F. Boyle, Val Gebski, (unknown), (unknown), Sarah‐Jane Dawson, Sherene Loi, Andrew Redfern, Janine Lombard, Andrew J. Spillane, (unknown), (unknown)	2
3	Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio 2020 ·The Breast ·(unknown), Siew‐Kee Low, (unknown), Peter Fox, Bavanthi Balakrishnar, Sally Coulter, Peter de Bruijn, Stijn L.W. Koolen, Bo Gao, Jodi Lynch, Nicholas Zdenkowski, Rina Hui, Christopher Liddle, Ron H.J. Mathijssen, Nicholas Wilcken, Mark Wong, Howard Gurney	4
4	Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study 2020 ·Brain Behavior & Immunity - Health ·Barbara Cameron, Kate Webber, Hongshou Li, Barbara Bennett, F. Boyle, Paul de Souza, Nicholas Wilcken, Jodi Lynch, Michael Friedländer, David Goldstein, Andrew R. Lloyd	11
5	Physical Activity for Symptom Management in Women With Metastatic Breast Cancer: A Randomized Feasibility Trial on Physical Activity and Breast Metastases 2019 ·Journal of Pain and Symptom Management ·Jasmine Yee, Glen M. Davis, Daniel Hackett, Jane Beith, Nicholas Wilcken, David C. Currow, Jon Emery, Jane Phillips, Andrew Martin, Rina Hui, Michelle Harrison, Eva Segelov, Sharon L. Kilbreath	48
6	Fulvestrant for hormone-sensitive metastatic breast cancer 2017 ·Cochrane Database of Systematic Reviews ·(unknown), Annabel Goodwin, Nicholas Wilcken	64
7	Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study 2016 ·Clinical Cancer Research ·Peter Fox, Rosemary L. Balleine, (unknown), Bo Gao, Bavanthi Balakrishnar, Alexander M. Menzies, (unknown), Sayed Ali, Val Gebski, Pamela Provan, Sally Coulter, Christopher Liddle, Rina Hui, Richard Kefford, Jodi Lynch, Mark Wong, Nicholas Wilcken, Howard Gurney	64
8	Systemic treatment of HER2‐positive metastatic breast cancer: A systematic review 2014 ·Asia-Pacific Journal of Clinical Oncology ·Nicholas Wilcken, Nicholas Zdenkowski, Michelle White, Ray Snyder, Ken Pittman, Paul N. Mainwaring, Michael Green, Prudence A. Francis, Richard de Boer, Maree Colosimo, (unknown), Jacquie Chirgwin, Jane Beith, Richard H. Bell	17
9	Systemic treatment of HER2+ metastatic breast cancer: Clinical conundrums and future perspectives 2014 ·Asia-Pacific Journal of Clinical Oncology ·Richard de Boer, Jane Beith, Jacquie Chirgwin, Sue Chua, Maree Colosimo, Prudence A. Francis, Michael Green, Ken Pittman, Michelle White, Nicholas Wilcken, Nicholas Zdenkowski, Richard H. Bell	1
10	Physical activity and fitness in women with metastatic breast cancer 2014 ·Journal of Cancer Survivorship ·Jasmine Yee, Glen M. Davis, Jane Beith, Nicholas Wilcken, David C. Currow, Jon Emery, Jane Phillips, Andrew Martin, Rina Hui, Michelle Harrison, Eva Segelov, Sharon L. Kilbreath	57
11	Post-cancer fatigue is not associated with immune activation or altered cytokine production 2012 ·Annals of Oncology ·Barbara Cameron, Barbara Bennett, Hongshou Li, F. Boyle, (unknown), Nicholas Wilcken, Michael Friedländer, David Goldstein, Andrew R. Lloyd	16
12	Use of non‐anthracycline regimens in early stage breast cancer in Australia 2010 ·Asia-Pacific Journal of Clinical Oncology ·Richard H. De Boer, Arlene Chan, Ben Tran, Nicholas Wilcken	7
13	Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype 2007 ·Clinical Pharmacology & Therapeutics ·Howard Gurney, Ma‐Li Wong, Rosemary L. Balleine, Laurent P. Rivory, Andrew J. McLachlan, Janelle M. Hoskins, Nicholas Wilcken, Christine L. Clarke, Graham J. Mann, Michael D. Collins, (unknown), Kevin Lynch, Horst Schran	115
14	Selective Mastectomy in the Management of Locally Advanced Breast Cancer 2007 ·International Journal of Radiation OncologyBiologyPhysics ·Verity Ahern, John Boyages, Val Gebski, Dominic H. Moon, Nicholas Wilcken	2
15	Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial 2007 ·The Lancet Oncology ·Martin R. Stockler, Rachel O’Connell, Anna K. Nowak, David Goldstein, Jane Turner, Nicholas Wilcken, David Wyld, Ehtesham Abdi, (unknown), Philip Beale, Michael Jefford, Haryana M. Dhillon, Stéphane Héritier, Candace Carter, Ian B. Hickie, R. John Simes	115
16	Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer 2006 ·Psycho-Oncology ·V. Duric, Phyllis Butow, Louise Sharpe, Frances Boyle, Jane Beith, Nicholas Wilcken, Stéphane Héritier, Alan S. Coates, R. John Simes, Martin R. Stockler	41
17	Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? 2005 ·Annals of Oncology ·V. Duric, Martin R. Stockler, Stéphane Héritier, F. Boyle, Jane Beith, A. Sullivan, Nicholas Wilcken, Alan S. Coates, R. J. Simes	100
18	Hormone replacement therapy and breast cancer: estimate of risk 2005 ·BMJ ·Nathan Coombs, Richard Taylor, Nicholas Wilcken, John Boyages	9
19	HRT and breast cancer: Impact on population risk and incidence 2005 ·European Journal of Cancer ·Nathan Coombs, Richard Taylor, Nicholas Wilcken, John Boyages	22
20	Different points of action of retinoids and anti-estrogens in G1 phase identified in synchronized T-47D breast cancer cells 1997 ·International Journal of Cancer ·Nicholas Wilcken, Elizabeth A. Musgrove, Robert L. Sutherland	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact